Methods of treating B-cell proliferative disorder
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one e...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
13.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg. |
---|---|
Bibliography: | Application Number: US202318206290 |